Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 1.12B +8.1% |
| Revenue (ttm) | 1.04B +4.0% |
| Net Income | -63.32M |
| EPS | -0.93 |
| Shares Out | 69.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,431,356 |
| Open | 15.64 |
| Previous Close | 15.68 |
| Day's Range | 15.38 - 16.13 |
| 52-Week Range | 12.26 - 29.65 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 27.86 (+72.94%) |
| Earnings Date | Nov 5, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $27.86, which is an increase of 72.94% from the latest price.
News
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial m...
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Diabetes Care Transcript: Canaccord Genuity's 46th Annual Growth Conference
Diabetes pump therapy remains under-penetrated, and the company is driving growth through product innovation, a new pay-as-you-go pharmacy model, and international direct sales expansion. Key upcoming milestones include the launch of a tubeless pump and a fully closed loop system, with a focus on affordability, clinical outcomes, and operational efficiency.
Tandem Diabetes Care Earnings Call Transcript: Q2 2026
Record Q2 with 10%+ pump shipment growth, 6% sales increase, and 57% gross margin. Pharmacy PayGo adoption reached 10% of U.S. sales, and Mobi Tubeless FDA submission sets up a major H2 launch. Guidance reaffirmed with highest margins expected in Q4.
Tandem Diabetes Care Slides: Q2 2026
Tandem Diabetes Care has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Tandem Diabetes Care Earnings release: Q2 2026
Tandem Diabetes Care released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q2 2026
Tandem Diabetes Care has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter end...
Tandem Diabetes Care Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Cana...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial ...
Tandem Diabetes Care Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted strong momentum in product innovation, including the CE Mark for pregnancy indication and the upcoming Mobi Tubeless launch. The pharmacy channel transition is progressing, aiming to reduce out-of-pocket costs and drive growth, while international expansion and new technology initiatives are set to further strengthen market position.
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes.
Tandem Diabetes Care Transcript: AGM 2026
The meeting covered six key proposals, including director elections, executive compensation, and amendments to governance documents. All proposals passed, and no questions were raised on meeting matters.
Tandem Diabetes Care Transcript: Bank of America Global Healthcare Conference 2026
Record Q1 results were achieved amid major business model changes, including the PayGo pharmacy launch and direct international sales. Pharmacy channel coverage is expanding, new product launches like Mobi are set to drive growth, and profitability is improving with strong customer retention.
Tandem Diabetes Care Earnings Call Transcript: Q1 2026
Record Q1 pump shipments and sales, margin expansion, and positive cash flow highlight strong execution. New product launches, pharmacy channel transition, and international expansion support reaffirmed 2026 guidance and long-term growth outlook.
Tandem Diabetes Care Earnings release: Q1 2026
Tandem Diabetes Care released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q1 2026
Tandem Diabetes Care has published its Q1 2026 quarterly earnings report on May 7, 2026.
Tandem Diabetes Care Slides: Q1 2026
Tandem Diabetes Care has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Tandem Diabetes Care Announces First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2...
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the ...
Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes.
Tandem Diabetes Care Proxy statement: Proxy filing
Tandem Diabetes Care filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Tandem Diabetes Care Proxy statement: Proxy filing
Tandem Diabetes Care filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial m...